title: Effect of stent thrombosis on the risk-benefit balance of drug-eluting stents and bare metal stents.
abstract: OBJECTIVE
  To determine the difference in the risk of stent thrombosis between drug-eluting stents (DES) and bare-metal stents (BMS) and to assess the clinical implications.
  
  
  METHODS
  A retrospective analysis of two cohorts of patients treated at our center with either > or =1 paclitaxeleluting stents (PES) (n=430) or > or =1 BMSs (n=1230) during 2003-2004 was carried out using propensity score methods to compare the adjusted risks of stent thrombosis, instent restenosis, cardiovascular death, acute myocardial infarction (AMI), and target-lesion revascularization with the two stent types.
  
  
  RESULTS
  After a median follow-up of 46 months, there was a higher risk of stent thrombosis in PESs (hazard ratio [HR]=3; 95% confidence interval [CI], 1.2-7.1] though the risk of in-stent restenosis was lower (HR=0.3; 95% CI, 0.2-0.7]. There was no difference in the risk of cardiovascular death, AMI or target-lesion revascularization. With PESs, the risks of target-lesion revascularization (HR=0.33; 95% CI, 0.2-0.7) and in-stent restenosis (HR=0.32; 95% CI, 0.2-0.7) were reduced during the first year of follow-up. After this time, the risks of target-lesion revascularization (HR=1.8; 95% CI, 1-3.2) and very late stent thrombosis (HR=12.8; 95% CI, 3-55.1) both increased.
  
  
  CONCLUSIONS
  Our findings indicate that the balance of risks and benefits of PESs compared with BMSs is different in the early and late periods after stent implantation. The greatly increased risk of very late stent thrombosis in PESs could cancel out the clinical benefits associated with the reduction in in-stent restenosis observed in PESs relative to BMSs.
authors.affiliation: Complexo Hospitalario Universitario de A Coruña, Spain. xacobeflores@yahoo.es
authors.forename: Xacobe
authors.initials: X
authors.lastname: Flores-Ríos
authors.forename: Juan P
authors.initials: JP
authors.lastname: Abugattás-de Torres
authors.forename: Rosa
authors.initials: R
authors.lastname: Campo-Pérez
authors.forename: Pablo
authors.initials: P
authors.lastname: Piñón-Esteban
authors.forename: Guillermo
authors.initials: G
authors.lastname: Aldama-López
authors.forename: Jorge
authors.initials: J
authors.lastname: Salgado-Fernández
authors.forename: Ramón
authors.initials: R
authors.lastname: Calviño-Santos
authors.forename: José M
authors.initials: JM
authors.lastname: Vázquez-Rodríguez
authors.forename: Nicolás
authors.initials: N
authors.lastname: Vázquez-González
authors.forename: Alfonso
authors.initials: A
authors.lastname: Castro-Beiras
mesh_terms: D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000627:therapeutic use; D015331:Cohort Studies; D003328:Coronary Thrombosis / Q000453:epidemiology* / Q000209:etiology / Q000401:mortality; D054855:Drug-Eluting Stents / Q000009:adverse effects; D005260:Female; D005500:Follow-Up Studies; D006083:Graft Occlusion, Vascular / Q000517:prevention & control; D006801:Humans; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage / Q000627:therapeutic use; D012189:Retrospective Studies; D018570:Risk Assessment; D015607:Stents / Q000009:adverse effects
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel